Key result
Vericiguat reduces the risk of cardiovascular mortality or HF hospitalizations by an absolute event-rate reduction of 4.2 events per 100 patient-years (NNT=24).
Why the study?
Despite therapeutic advancements in HFrEF, residual risk of all-cause mortality and hospitalizations remains high.
Does vericiguat reduce cardiovascular mortality or HF hospitalizations in patients with worsening HFrEF?
Does vericiguat reduce cardiovascular mortality or HF hospitalizations in patients with worsening HFrEF?
Vericiguat provides a clinically meaningful reduction in cardiovascular mortality and heart failure hospitalizations for patients with worsening HFrEF on standard therapy.
Answers are grounded in this paper and cite their sources.
Vericiguat adds a targeted option to lower residual CV death/HF hospitalization risk in worsening HFrEF on GDMT; reinforces Class 2b guideline positioning.
INTRODUCTION: Despite significant therapeutic advancements in heart failure with reduced ejection fraction (HFrEF), the residual risk of all-cause mortality and hospitalizations remains high among patients with HFrEF. Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator which was approved by the US Food and Drug administration (FDA) in January 2021 for use in patients with symptomatic chronic HF and an ejection fraction less than 45% following a hospitalization for HF or the need for outpatient intravenous diuretics. AREAS COVERED: We provide a concise review of the pharmacology, clinical efficacy, and tolerability of vericiguat in HFrEF. We also discuss the role of vericiguat in current clinical practice. EXPERT OPINION: Vericiguat reduces the risk of cardiovascular mortality or HF hospitalizations by an absolute event-rate reduction of 4.2 events per 100 patient-years with a number needed to treat of 24 patients, on a background of guideline-directed medical therapy. Almost 90% of the patients with HFrEF were adherent to the 10 mg dose of vericiguat in the VICTORIA trial with a favorable tolerability and safety profile. Considering the high residual risk that persists in HFrEF, vericiguat has a role to improve outcomes among patients with worsening HFrEF.
No takes yet. Share an insight, caveat, or question.
Siddiqi et al. (2023) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Vericiguat was evaluated on Cardiovascular mortality or HF hospitalizations (ARR 4.2 events per 100 patient-years). Vericiguat reduces the risk of cardiovascular mortality or HF hospitalizations by an absolute event-rate reduction of 4.2 events per 100 patient-years (NNT=24).
Synapse has enriched 10 related papers. Consider them for comparative context: